Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is conducting a Phase 1/2 clinical study titled ‘A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration.’ This study aims to assess the safety, tolerability, and efficacy of a single intravitreal dose of SAR446597 in treating geographic atrophy due to age-related macular degeneration, a significant cause of vision loss.
The intervention being tested is SAR446597, delivered as a one-time intravitreal injection. This treatment is designed to potentially slow or halt the progression of geographic atrophy in affected individuals.
The study is interventional, with a randomized and sequential design. It employs a double-masking approach, meaning both participants and outcomes assessors are unaware of the treatment allocations. The primary goal is treatment efficacy.
The study is not yet recruiting, with an initial submission date of October 1, 2025, and a recent update on October 9, 2025. These dates are crucial as they mark the study’s progress and readiness to begin participant recruitment.
This study’s update could influence Sanofi’s stock performance and investor sentiment, as successful results may strengthen its position in the ophthalmology market. Competitors in the field may also be closely monitoring these developments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.